Vitamin D deficiency is a risk factor for multiple sclerosis.

Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.

Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.

Barriers to using screening tools included lack of time and lack of insurance compensation.

Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.

The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.

Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.

A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.

The EFFECT study compared the efficacy of dimethyl fumarate vs other disease-modifying therapies, including fingolimod and glatiramer acetate in patients with relapsing-remitting multiple sclerosis.

A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.

Study authors emphasize the rebound relapse phenomenon as a potential complication in the safety of fingolimod.

Application of technology developed in the gaming and computer control industry offers the opportunity to create new metrics with greater sensitivity and reproducibility.

The randomized, double-blind PARADIGM study compared the safety and efficacy of fingolimod and interferon β-1a in teens with relapsing-remitting MS.

The post-hoc analysis compared 6-month confirmed disability progression using patient data from PRISMS-2.

Ozanimod decreased both T2 and T1 brain lesions and brain volume loss in patients with relapsing multiple sclerosis.

Researchers aimed to determine the proportion of patients with early relapsing-remitting multiple sclerosis treated with natalizumab who achieve no evidence of disease activity at year 2.

Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.

Researchers examined patients’ disease course and the number of clinical attacks to determine the safety and efficacy of intravenous cladribine.

Obesity-associated lowering of vitamin D levels may not mediate the putative causal relationship between obesity and multiple sclerosis.

CRISP will determine the suitability of clozapine and risperidone as a treatment for progressive multiple sclerosis.